Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease

Eliyahu V. Khankin, Walter P. Mutter, Hector Tamez et al. · 2010

Read Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease by Eliyahu V. Khankin, Walter P. Mutter, Hector Tamez et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0009246.txt.

Description

Eliyahu Khankin and co-authors published this kidney study in PLOS ONE in 2010. Erythropoietin is a hormone used to treat anemia in kidney patients. Many patients with end-stage renal disease respond poorly to it. Doctors then raise the dose again and again, often without reaching target blood counts.

The team investigated one suspect: a soluble form of the erythropoietin receptor floating in the blood. Such loose receptors could soak up the hormone before it reaches bone marrow. They report that this soluble receptor contributes to the resistance seen in these patients. The finding suggests a new way to predict, and perhaps reduce, poor responses.

Catalog record

CREATOREliyahu V. Khankin, Walter P. Mutter, Hector Tamez et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009246

Browse the full library · About the Tower of Babel